Haemanthus
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 2
- Theranos whistleblower warns AI boom enables deception
Theranos whistleblower Tyler Shultz told The San Francisco Standard that AI capabilities are unusually difficult to verify, making it hard to distinguish genuinely new technology from a ChatGPT wrapper. He urged investors to conduct real due diligence and said the boom creates opportunities for Theranos-style deception. Shultz also criticized restrictive nondisclosure and non-disparagement agreements as barriers for AI workers seeking to contact regulators or lawyers.
TechCrunch AI · 🔥 0 - Haemanthus advances Raman spectroscopy and AI medical diagnostics
Haemanthus, a medical-testing startup founded by Billy Evans, is combining Raman spectroscopy with AI to identify disease-related biomarkers in blood, saliva and urine. Its October 20 patent grant covers measuring molecular vibration-coupling signals, and the company has disclosed further work on coherent Raman detection and photonic integrated circuits. MIT Technology Review China reported that Haemanthus has not yet published complete clinical data or a sufficiently validated commercial diagnostic product.
MIT科技评论中文 · 🔥 0
Experience and discussion from the community
Share my Haemanthus experienceAsk about Haemanthus
Nobody has shared their experience with Haemanthus yet.